Literature DB >> 17268940

Assessing a pharmacist-run anaemia educational programme for patients with chronic renal insufficiency.

B Allenet1, C Chen, T Romanet, P Vialtel, J Calop.   

Abstract

OBJECTIVE: Assessment of a pharmacist-run anaemia educational programme for patients with chronic renal insufficiency.
SETTING: Nephrology Department, Grenoble Hospital, France.
METHOD: A 12-week prospective study, using a before-after intervention design. Included in the study were predialysis outpatients with a haemoglobin level < 10 g/dl, de novo EPO prescription; judged qualified by the nephrologist for self-injections; accepting self-injections. The intervention was a single one-hour individual session between the pharmacist and the patient to target (1) medical and therapeutic information; (2) information on the device, a pen used with a cartridge of beta epoietin; (3) training with the pen; and (4) self-injection of the first dose by the patient, in front of the pharmacist. Main outcome measures were knowledge (7-item questionnaire); handling skills (observation) and Quality of Life (1 Likert scale on apprehension towards self-injections and 3 Linear Analog Scales on energy, daily activities, and general well-being); compliance (self-report on self-administered injections) and haemoglobin level.
RESULTS: Ten patients were followed for 3 months after intervention. The evolution of the knowledge was positive but not statistically significant after the programme (80% of good answers before; 93% 3 months later). Concerning the patients' skills, difficulties with the pen were important at inclusion, (1) to reset the pen into zero position (2.8 tries/patient +/- 1.8); (2) to insert a new cartridge (1.9 +/- 1.1); and (3) to take air out of the cartridge (2.3 +/- 1.2). After the session, results were satisfactory, since 3 months later, all patients were still on self-injections. QoL improved significantly over the study period respectively on energy, daily activities, and general well-being. The mean level of compliance remained above 90% at 3 months for 8 out of 10 patients. Patients reached the haemoglobin target value of 11 g/dl during the second month of treatment.
CONCLUSION: A tailored educational programme conducted by a pharmacist is beneficial for anaemia patients with chronic renal insufficiency. The programme seems to result in a high level of compliance, leading to an optimal haemoglobin level within two months.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17268940     DOI: 10.1007/s11096-005-4800-4

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  14 in total

1.  Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit.

Authors:  L L To; C P Stoner; S N Stolley; J D Buenviaje; T W Ziegler
Journal:  Am J Health Syst Pharm       Date:  2001-11-01       Impact factor: 2.637

2.  Use of erythropoietin before the initiation of dialysis and its impact on mortality.

Authors:  J Fink; S Blahut; M Reddy; P Light
Journal:  Am J Kidney Dis       Date:  2001-02       Impact factor: 8.860

3.  Current management of anemia in adult hemodialysis patients with end-stage renal disease.

Authors:  Diane L Frankenfield; Curtis A Johnson
Journal:  Am J Health Syst Pharm       Date:  2002-03-01       Impact factor: 2.637

Review 4.  Patient education: can it maximize the success of therapy?

Authors:  T Golper
Journal:  Nephrol Dial Transplant       Date:  2001       Impact factor: 5.992

5.  Compliance with subcutaneous erythropoietin in peritoneal dialysis patients.

Authors:  P Nicoletta; J Bernardini; C Dacko; C Terry; L Fried
Journal:  Adv Perit Dial       Date:  2000

6.  European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure.

Authors: 
Journal:  Nephrol Dial Transplant       Date:  1999       Impact factor: 5.992

7.  Factors influencing erythropoietin compliance in peritoneal dialysis patients.

Authors:  Lori D Wazny; Biljana B Stojimirovic; Paul Heidenheim; Peter G Blake
Journal:  Am J Kidney Dis       Date:  2002-09       Impact factor: 8.860

Review 8.  A rationale for an individualized administration frequency of epoetin beta: a clinical perspective.

Authors:  Lars Weiss
Journal:  Nephrol Dial Transplant       Date:  2002       Impact factor: 5.992

9.  Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients.

Authors:  H T Robertson; N R Haley; M Guthrie; D Cardenas; J W Eschbach; J W Adamson
Journal:  Am J Kidney Dis       Date:  1990-04       Impact factor: 8.860

Review 10.  Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system.

Authors:  J Radermacher; K M Koch
Journal:  Clin Nephrol       Date:  1995-11       Impact factor: 0.975

View more
  3 in total

1.  The missing piece: Clinical pharmacists enhancing the interprofessional nephrology clinic model.

Authors:  Chelsea E Hawley; Laura K Triantafylidis; Julie M Paik
Journal:  J Am Pharm Assoc (2003)       Date:  2019-06-21

Review 2.  Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review.

Authors:  Gunar Stemer; Rosa Lemmens-Gruber
Journal:  BMC Nephrol       Date:  2011-07-22       Impact factor: 2.388

3.  Management of Drug-Drug Interactions among Critically Ill Patients with Chronic Kidney Disease: Impact of Clinical Pharmacist's Interventions.

Authors:  Mina Aghili; Meera Neelathahalli Kasturirangan
Journal:  Indian J Crit Care Med       Date:  2021-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.